Skip to main content

Advertisement

SpringerLink
Log in

Resistant hypertension

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Recent clinical trials suggest that resistant hypertension is increasingly common. In the majority of patients, uncontrolled hypertension is due to persistent elevation of the systolic blood pressure. Older age and obesity are associated with poor blood pressure control. Other contributing factors include severity of the underlying hypertension and renal insufficiency. Poor patient adherence is thought be a common cause of medication resistance. Exogenous substances such as nonsteroidal anti-inflammatory drugs, oral contraceptives, and sympathomimetic agents can interfere with treatment. The prevalence of secondary causes of hypertension increases with age, especially atherosclerotic renal artery stenosis. Recent reports suggest that primary aldosteronism may be the most common secondary cause of hypertension. It should be considered in all patients with resistant hypertension. Effective treatment of resistant hypertension requires identification and reversal of contributing factors and/or secondary causes of hypertension. Pharmacologic therapy should utilize combination therapy, including a long-acting diuretic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446.

  2. Black HR, Elliott WJ, Neaton, et al.: Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001, 37:12–18. Documents blood pressure response rates and number of drugs used when using an aggressive, stepped-care approach to treating blood pressure in older patients.

    PubMed  CAS  Google Scholar 

  3. Cushman WC, Black HR, Probstfield JL, et al., for the ALLHAT Group: Blood pressure control in the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack (ALLHAT) [abstract]. Am J Hypertens 1998, 11:17A.

    Article  Google Scholar 

  4. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1999, 350:757–764.

    Article  Google Scholar 

  5. Kjeldsen SF, Dahlof B, Devereux R, et al., for the LIFE Study Group: One year of antihypertensive treatment in patients with LVH: the LIFE Study [abstract]. Am J Hypertens 1999, 12:142A.

    Article  Google Scholar 

  6. Hyman DJ, Pavlik VN: Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001, 345:479–486. Important study identifying patient characteristics related to poorly controlled hypertension.

    Article  PubMed  CAS  Google Scholar 

  7. Lloyd-Jones DM, Evans JC, Larson, et al.: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594–599. Excellent report on blood pressure control rates among hypertensive Americans. Clearly demonstrates that the poor blood pressure control is overwhelmingly due to lack of systolic blood pressure control among treated subjects.

    PubMed  CAS  Google Scholar 

  8. Inui TS, Carter WB, Pecoraro RE: Screening for noncompliance among patients with hypertension: is self-report the best available measure? Med Care 1981, 19:1061–1064.

    Article  PubMed  CAS  Google Scholar 

  9. Sackett DL, Haynes RB, Gibson ES, et al.: Randomized clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975, 1:1205–1207.

    Article  PubMed  CAS  Google Scholar 

  10. Management of patient compliance in the treatment of hypertension: report of the NHLBI Working Group.Hypertension 1982, 4:415–423.

    Google Scholar 

  11. Yakovlevitch M, Black HR: Resistant hypertension in tertiary care clinic. Arch Intern Med 1991, 151:1786–1792.

    Article  PubMed  CAS  Google Scholar 

  12. Messerli FH, Ventura HO, Amodeo C: Osler’s maneuver and pseudohypertension. N Engl J Med 1985, 312:1548–1551.

    Article  PubMed  CAS  Google Scholar 

  13. Zuschke CA, Pettyjohn FS: Pseudohypertension. South Med J 1995, 88:1185–1190.

    PubMed  CAS  Google Scholar 

  14. Hla K, Samsa G, Stoneking H, et al.: Observer variability of Osler’s maneuver in dection of pseudohypertension. J Clin Epidemiol 1991, 44:513–518.

    Article  PubMed  CAS  Google Scholar 

  15. Hla KM, Feussner JR: Screening for pseudohypertension: a quantitative, noninvasive approach. Arch Intern Med 1988, 148:673–676.

    Article  PubMed  CAS  Google Scholar 

  16. Khoury S, Yarows SA, O’Brien TK, et al.: Ambulatory blood pressure recording in a nonacademic setting. Effect of age and sex. Am J Hypertens 1992, 5:616–623.

    PubMed  CAS  Google Scholar 

  17. Pickering TG, James GD, Boddie C, et al.: How common is white coat hypertension? JAMA 1988, 259:225–228.

    Article  PubMed  CAS  Google Scholar 

  18. Lerman CE, Brody DS, Hui T, et al.: The white-coat hypertension response: prevalence and predictors. J Gen Intern Med 1989, 4:226–231.

    Article  PubMed  CAS  Google Scholar 

  19. Verdecchia P, Porcellati C, Schillaci G, et al.: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994, 24:793–801.

    PubMed  CAS  Google Scholar 

  20. Khattar RS, Senion R, Lahiri A: Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation 1998, 98:1892–1987.

    PubMed  CAS  Google Scholar 

  21. Redon J, Campos C, Narciso ML, et al.: Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998, 31:712–718. An important prospective study demonstrating a high prevalence of white coat hypertension among patients with resistant hypertension, and the generally benign cardiovascular outcome of such patients.

    PubMed  CAS  Google Scholar 

  22. Palatini P, Dorigatti F, Roman E, et al., on behalf of the Harvest Study Investigators: White-coat hypertension: a selection bias? J Hypertens 1998, 16:977–984.

    Article  PubMed  CAS  Google Scholar 

  23. Elliott P, Stamler J, Nichols R, et al., for the Intersalt Cooperative Research Group: Intersalt revisited: further analyses of 24-hour sodium excretion and blood pressure within and across populations. BMJ 1996, 312:1249–1253.

    PubMed  CAS  Google Scholar 

  24. Elliott P: Observational studies of salt and blood pressure. Hypertension 1991, 17(Suppl I):I3-I8.

    PubMed  CAS  Google Scholar 

  25. Weinberger MH: Salt-sensitivity of blood pressure in humans. Hypertension 1996, 27[part 2]:481–490.

    Google Scholar 

  26. Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001, 21:1–15.

    Article  PubMed  CAS  Google Scholar 

  27. Swan SK, Rudy DW, Lasseter KC, et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000, 133:1–9.

    PubMed  CAS  Google Scholar 

  28. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289–300.

    PubMed  CAS  Google Scholar 

  29. Radack KL, Deck CC, Bloomfield SS: Ibuprofen interferes with the efficacy of antihypertensive drugs. Ann Intern Med 1987, 107:628–635.

    PubMed  CAS  Google Scholar 

  30. MacMahon S: Alcohol consumption and hypertension. Hypertension 1987, 9:111–121.

    PubMed  CAS  Google Scholar 

  31. Henningsen NC, Ohlsson O, Mattiasson I, et al.: Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand 1980, 207:245–251.

    Article  PubMed  CAS  Google Scholar 

  32. Aquilera MT, de la Sierra A, Coca A, et al.: Effect of alcohol abstinence on blood pressure: Assessment by 24-hr ambulatory blood pressure monitoring. Hypertension 1999, 33:653–657.

    Google Scholar 

  33. Ashley FW Jr, Kannel WB: Relation of weight change to changes in atherogenic traits: the Framingham Study. J Chron Dis 1974, 27:103–114.

    Article  PubMed  Google Scholar 

  34. Modan M, Almog S, Fuchs Z, et al.: Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 1991, 17:656–573.

    Google Scholar 

  35. Grote L, Ploch T, Heitmann J, et al.: Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999, 160:1875–1882.

    PubMed  CAS  Google Scholar 

  36. Nieto FJ, Young TB, Lind BK, et al., for the Sleep Heart Health Study: Association of sleep disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000, 283:1829–1836.

    Article  PubMed  CAS  Google Scholar 

  37. Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378–1384.

    Article  PubMed  CAS  Google Scholar 

  38. Logan AG, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2002, 20:1–7. Important study demonstrating very high prevalence of undiagnosed sleep apnea among patients with resistant hypertension.

    Article  Google Scholar 

  39. Grote L, Hedner J, Peter JH: Sleep-related breathing disorder is an independent factor for uncontrolled hypertension. J Hypertens 2000, 18:679–685.

    Article  PubMed  CAS  Google Scholar 

  40. Silverberg DS, Oksenberg A: Are sleep-related breathing disorders important contributing factors to the production of essential hypertension. Curr Hypertens Rep 2001, 3:209–215.

    PubMed  CAS  Google Scholar 

  41. Dimsdale JE, Loredo JS, Profant J: Effect of continuous positive airway pressure on blood pressure: a placebo trial. Hypertension 2000, 35:144–147.

    PubMed  CAS  Google Scholar 

  42. Anderson GH Jr, Blakeman N, Streeten DHP: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994, 12:609–615.

    Article  PubMed  Google Scholar 

  43. Safian RD, Textor S: Renal-artery stenosis. N Engl J Med 2001, 344:431–442. An excellent review article on diagnosis and treatment of renal artery stenosis.

    Article  PubMed  CAS  Google Scholar 

  44. Bonelli FS, McKusick MA, Textor SC, et al.: Renal artery angioplasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc 1995, 70:1041–1052.

    PubMed  CAS  Google Scholar 

  45. Canzanello VJ, Millan VG, Spiegel JE, et al.: Percutaneous transluminal renal angioplasty in management of atherosclerotic Renovascular hypertension: results in 100 patients. Hypertension 1989, 13:163–172.

    PubMed  CAS  Google Scholar 

  46. Lim PO, Dow E, Grennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 14:311–315.

    Article  PubMed  CAS  Google Scholar 

  47. Loh K-C, Koay ES, Khaw M-C, et al.: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000, 85:2854–2859.

    Article  PubMed  CAS  Google Scholar 

  48. Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315–318.

    PubMed  CAS  Google Scholar 

  49. Rayner BL, Opie LH, Davidson JS: The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394–400.

    PubMed  CAS  Google Scholar 

  50. Galley BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: the plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699–705.

    Article  Google Scholar 

  51. Stowasser M: Primary aldosteronism: rare bird or common cause of secondary hypertension? Curr Hypertens Rep 2001, 3:230–239.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 520 ZRB, 703 South 19th Street, 35294, Birmingham, AL, USA

    David A. Calhoun MD, Mohammad A. Zaman MD & Mari K. Nishizaka MD

Authors
  1. David A. Calhoun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad A. Zaman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mari K. Nishizaka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calhoun, D.A., Zaman, M.A. & Nishizaka, M.K. Resistant hypertension. Current Science Inc 4, 221–228 (2002). https://doi.org/10.1007/s11906-002-0011-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-002-0011-8

Keywords

Search

Navigation